Publications
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
- Date de publication : 2014-07-21
Référence
Bujold E, Roberge S, Nicolaides KH. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat. Diagn. 2014;34:642-8. doi: 10.1002/pd.4403. PubMed PMID: 24799357.
Information Complémentaire
Mot(s) Clé(s)
aspirin dose-response relationship, drug female humans placenta diseases placentation pregnancy pregnancy complications pregnancy outcome randomized controlled trials as topic
Résumé
Meta-analysis of randomized studies on the use of low-dose aspirin in women at high risk of preeclampsia (PE) has demonstrated that if treatment is initiated at ≤16 weeks' gestation, there is significant reduction in the risk of PE [relative risk (RR) 0.47, 95% confidence interval (CI) 0.36-0.62], fetal growth restriction (RR 0.46, 95% CI 0.33-0.64), preterm birth (RR 0.35, 95% CI 0.22-0.57) and perinatal death (RR 0.41, 95% CI 0.19-0.92), whereas the effect of treatment after 16 weeks is substantially less (RR 0.78, 95% CI 0.61-0.99; RR 0.98, 95% CI 0.88-1.08; RR 0.90, 95% CI 0.83-0.97; and RR 0.93, 95% CI 0.73-1.19, respectively). Moreover, the decrease in the risk of PE from early onset treatment seems to be related to the dose of aspirin, and a dose of >80 mg daily should be considered for optimal benefits.
